By SME WHO? Failure has an image problem in the life sciences. Founders don’t talk about it, scientists spend years trying to prevent it, and boards and investors rarely celebrate it publicly. But some of the most valuable outcomes in drug development are the ones that reveal, quickly and conclusively, that a program, hypothesis, or strategy is unlikely to create ... Read More The post Failure Is a Competitive Advantage in Biotech appeared first on Lovelace Biomedical .